EP2111395A1 - Derives de phenyl- (4-phenyl-pyrimidin-2-yl) - amines comme inhibiteurs de ikk, leur preparation et leur compositions pharmaceutiques - Google Patents
Derives de phenyl- (4-phenyl-pyrimidin-2-yl) - amines comme inhibiteurs de ikk, leur preparation et leur compositions pharmaceutiquesInfo
- Publication number
- EP2111395A1 EP2111395A1 EP08761728A EP08761728A EP2111395A1 EP 2111395 A1 EP2111395 A1 EP 2111395A1 EP 08761728 A EP08761728 A EP 08761728A EP 08761728 A EP08761728 A EP 08761728A EP 2111395 A1 EP2111395 A1 EP 2111395A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- radicals
- products
- optionally substituted
- radical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 229940079593 drug Drugs 0.000 title claims abstract description 13
- 239000003458 I kappa b kinase inhibitor Substances 0.000 title claims abstract 3
- 238000002360 preparation method Methods 0.000 title claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- MUJKUTZQKCWMHD-UHFFFAOYSA-N n,4-diphenylpyrimidin-2-amine Chemical class N=1C=CC(C=2C=CC=CC=2)=NC=1NC1=CC=CC=C1 MUJKUTZQKCWMHD-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 72
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 71
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 48
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract description 47
- 125000003118 aryl group Chemical group 0.000 claims abstract description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 27
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 17
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 10
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 9
- -1 alkoxy radicals Chemical class 0.000 claims description 453
- 150000003254 radicals Chemical class 0.000 claims description 201
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 165
- 125000005843 halogen group Chemical group 0.000 claims description 144
- 125000004432 carbon atom Chemical group C* 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 63
- 229910052757 nitrogen Inorganic materials 0.000 claims description 63
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 61
- 150000007522 mineralic acids Chemical class 0.000 claims description 60
- 150000007524 organic acids Chemical class 0.000 claims description 60
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 58
- 235000005985 organic acids Nutrition 0.000 claims description 57
- 150000001875 compounds Chemical class 0.000 claims description 51
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 47
- 239000011707 mineral Substances 0.000 claims description 47
- 239000001257 hydrogen Substances 0.000 claims description 41
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 41
- 229910003827 NRaRb Inorganic materials 0.000 claims description 39
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 37
- 229920006395 saturated elastomer Polymers 0.000 claims description 36
- 238000006243 chemical reaction Methods 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 30
- 229910052799 carbon Inorganic materials 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 229910052717 sulfur Inorganic materials 0.000 claims description 28
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 24
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 24
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 22
- 229910052731 fluorine Inorganic materials 0.000 claims description 22
- 230000006870 function Effects 0.000 claims description 21
- 125000000623 heterocyclic group Chemical group 0.000 claims description 21
- 125000005842 heteroatom Chemical group 0.000 claims description 20
- 125000002757 morpholinyl group Chemical group 0.000 claims description 20
- 125000003386 piperidinyl group Chemical group 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 18
- 150000001412 amines Chemical class 0.000 claims description 17
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 125000004414 alkyl thio group Chemical group 0.000 claims description 15
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 15
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- 125000006239 protecting group Chemical group 0.000 claims description 15
- 125000002950 monocyclic group Chemical group 0.000 claims description 14
- 125000004193 piperazinyl group Chemical group 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 239000011737 fluorine Substances 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 13
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 12
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims description 12
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 12
- 229910052701 rubidium Inorganic materials 0.000 claims description 12
- 125000002393 azetidinyl group Chemical group 0.000 claims description 11
- 150000001721 carbon Chemical group 0.000 claims description 11
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 11
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 125000002541 furyl group Chemical group 0.000 claims description 11
- 230000005764 inhibitory process Effects 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 150000003457 sulfones Chemical class 0.000 claims description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 10
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 10
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 150000002576 ketones Chemical group 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000005493 quinolyl group Chemical group 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 9
- 125000002883 imidazolyl group Chemical group 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 125000000335 thiazolyl group Chemical group 0.000 claims description 9
- 102000001253 Protein Kinase Human genes 0.000 claims description 8
- 150000007513 acids Chemical class 0.000 claims description 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- 108060006633 protein kinase Proteins 0.000 claims description 8
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 8
- 125000004434 sulfur atom Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 7
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 5
- WNZHIZTYVGMRCZ-UHFFFAOYSA-N n-(2-aminoethyl)-4-[[4-(4-fluorophenyl)pyrimidin-2-yl]amino]-n-piperidin-4-ylbenzenesulfonamide Chemical compound C=1C=C(NC=2N=C(C=CN=2)C=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCN)C1CCNCC1 WNZHIZTYVGMRCZ-UHFFFAOYSA-N 0.000 claims description 5
- 125000005936 piperidyl group Chemical group 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 5
- 230000009466 transformation Effects 0.000 claims description 5
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004849 alkoxymethyl group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000002785 azepinyl group Chemical group 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000005303 dithiazolyl group Chemical group S1SNC(=C1)* 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 150000003462 sulfoxides Chemical group 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 3
- YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 claims description 3
- 125000003158 alcohol group Chemical group 0.000 claims description 3
- 238000010511 deprotection reaction Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 claims description 3
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000006243 carbonyl protecting group Chemical group 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000006268 reductive amination reaction Methods 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- 238000002483 medication Methods 0.000 claims 1
- 230000001012 protector Effects 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 231
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 41
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 30
- 102000003945 NF-kappa B Human genes 0.000 description 26
- 108010057466 NF-kappa B Proteins 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 235000010755 mineral Nutrition 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 12
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 9
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 150000001299 aldehydes Chemical class 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000012429 reaction media Substances 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 7
- 102100021892 Inhibitor of nuclear factor kappa-B kinase subunit alpha Human genes 0.000 description 7
- 101710110357 Inhibitor of nuclear factor kappa-B kinase subunit alpha Proteins 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 125000001174 sulfone group Chemical group 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 150000003230 pyrimidines Chemical class 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 102000001284 I-kappa-B kinase Human genes 0.000 description 4
- 108060006678 I-kappa-B kinase Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 229910005965 SO 2 Inorganic materials 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000005620 boronic acid group Chemical class 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 229960005419 nitrogen Drugs 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- QQXLDOJGLXJCSE-KNVOCYPGSA-N tropinone Chemical compound C1C(=O)C[C@H]2CC[C@@H]1N2C QQXLDOJGLXJCSE-KNVOCYPGSA-N 0.000 description 4
- QTFFSCFLCIESNQ-UHFFFAOYSA-N 2-[(2-chloropyrimidin-4-yl)amino]benzenesulfonyl chloride hydrochloride Chemical compound C1=CC=C(C(=C1)NC2=NC(=NC=C2)Cl)S(=O)(=O)Cl.Cl QTFFSCFLCIESNQ-UHFFFAOYSA-N 0.000 description 3
- UYHSQVMHSFXUOA-UHFFFAOYSA-N 2-methylthiouracil Chemical compound CSC1=NC=CC(O)=N1 UYHSQVMHSFXUOA-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 3
- ROMORJMRLXNBPJ-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[4-[4-[methyl(2-methylsulfonylethyl)amino]piperidin-1-yl]sulfonylphenyl]pyrimidin-2-amine Chemical compound C1CC(N(CCS(C)(=O)=O)C)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=CC(C=2C=CC(F)=CC=2)=N1 ROMORJMRLXNBPJ-UHFFFAOYSA-N 0.000 description 3
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 3
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 3
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 238000006114 decarboxylation reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 150000004965 peroxy acids Chemical class 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- LUXZSFUVMDGVNE-UHFFFAOYSA-N 2-anilino-1h-pyrimidin-6-one Chemical compound OC1=CC=NC(NC=2C=CC=CC=2)=N1 LUXZSFUVMDGVNE-UHFFFAOYSA-N 0.000 description 2
- WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
- ULXCXFILCWOMDO-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[4-[4-(methylamino)piperidin-1-yl]sulfonylphenyl]pyrimidin-2-amine Chemical compound C1CC(NC)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=CC(C=2C=CC(F)=CC=2)=N1 ULXCXFILCWOMDO-UHFFFAOYSA-N 0.000 description 2
- AVJMOQXWVQGQDP-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[4-[4-[1h-imidazol-2-ylmethyl(methyl)amino]piperidin-1-yl]sulfonylphenyl]pyrimidin-2-amine Chemical compound C1CN(S(=O)(=O)C=2C=CC(NC=3N=C(C=CN=3)C=3C=CC(F)=CC=3)=CC=2)CCC1N(C)CC1=NC=CN1 AVJMOQXWVQGQDP-UHFFFAOYSA-N 0.000 description 2
- TYTCTCRCAJYECK-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[4-[4-[methyl(quinolin-8-ylmethyl)amino]piperidin-1-yl]sulfonylphenyl]pyrimidin-2-amine Chemical compound C=1C=CC2=CC=CN=C2C=1CN(C)C(CC1)CCN1S(=O)(=O)C(C=C1)=CC=C1NC(N=1)=NC=CC=1C1=CC=C(F)C=C1 TYTCTCRCAJYECK-UHFFFAOYSA-N 0.000 description 2
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 2
- RKFXCEZKAYKZOX-UHFFFAOYSA-N 4-[[4-(4-fluorophenyl)pyrimidin-2-yl]amino]-n-methyl-n-piperidin-4-ylbenzenesulfonamide Chemical compound C=1C=C(NC=2N=C(C=CN=2)C=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(C)C1CCNCC1 RKFXCEZKAYKZOX-UHFFFAOYSA-N 0.000 description 2
- GNFKGFRWERSGIY-UHFFFAOYSA-N 4-chloro-n-phenylpyrimidin-2-amine Chemical compound ClC1=CC=NC(NC=2C=CC=CC=2)=N1 GNFKGFRWERSGIY-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102000003910 Cyclin D Human genes 0.000 description 2
- 108090000259 Cyclin D Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 2
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 2
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 2
- 229910019213 POCl3 Inorganic materials 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 150000005840 aryl radicals Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000037011 constitutive activity Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- UGRCIMVEVAMHKU-LBPRGKRZSA-N (r)-(4-fluorophenyl)-piperidin-4-ylmethanamine Chemical compound C1([C@@H](N)C=2C=CC(F)=CC=2)CCNCC1 UGRCIMVEVAMHKU-LBPRGKRZSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- VLXSIHLNPYRFFN-UHFFFAOYSA-N 1,4-dioxane;methanol Chemical compound OC.C1COCCO1 VLXSIHLNPYRFFN-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- HUWXQIAHXDZEAE-UHFFFAOYSA-N 1-[4-[(4-chloropyrimidin-2-yl)amino]phenyl]sulfonyl-4-(pyrrolidin-1-ylmethyl)piperidin-4-ol Chemical compound C1CN(S(=O)(=O)C=2C=CC(NC=3N=C(Cl)C=CN=3)=CC=2)CCC1(O)CN1CCCC1 HUWXQIAHXDZEAE-UHFFFAOYSA-N 0.000 description 1
- WUIJTQZXUURFQU-UHFFFAOYSA-N 1-methylsulfonylethene Chemical compound CS(=O)(=O)C=C WUIJTQZXUURFQU-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical class C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- PQHKCTZIGDLPPT-UHFFFAOYSA-N 2-[(2-chloro-5-fluoropyrimidin-4-yl)amino]benzenesulfonyl chloride hydrochloride Chemical compound Cl.FC=1C(=NC(=NC1)Cl)NC1=C(C=CC=C1)S(=O)(=O)Cl PQHKCTZIGDLPPT-UHFFFAOYSA-N 0.000 description 1
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
- SEUSFEKWVIFWTN-UHFFFAOYSA-N 2-aminopyrimidine-5-carbonitrile Chemical class NC1=NC=C(C#N)C=N1 SEUSFEKWVIFWTN-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- GKFFFOLFBJUEFN-UHFFFAOYSA-N 2-n,4-n-diphenylpyrimidine-2,4-diamine Chemical class C=1C=NC(NC=2C=CC=CC=2)=NC=1NC1=CC=CC=C1 GKFFFOLFBJUEFN-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- SFKAYSQAVXEORK-UHFFFAOYSA-N 3-azabicyclo[3.2.1]octan-8-amine Chemical compound C1NCC2CCC1C2N SFKAYSQAVXEORK-UHFFFAOYSA-N 0.000 description 1
- DFJMKIFTLAAZEO-UHFFFAOYSA-N 3-azabicyclo[3.3.1]nonan-9-amine Chemical compound C1CCC2CNCC1C2N DFJMKIFTLAAZEO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- DPALDESLDSLUGD-UHFFFAOYSA-N 4-(4-fluorophenyl)pyrimidine Chemical compound C1=CC(F)=CC=C1C1=CC=NC=N1 DPALDESLDSLUGD-UHFFFAOYSA-N 0.000 description 1
- KVPDUDGJCYNUMH-UHFFFAOYSA-N 4-(pyrrolidin-1-ylmethyl)piperidin-4-ol Chemical compound C1CCCN1CC1(O)CCNCC1 KVPDUDGJCYNUMH-UHFFFAOYSA-N 0.000 description 1
- UYSDJCZTLQZLKL-UHFFFAOYSA-N 4-(pyrrolidin-1-ylmethyl)piperidin-4-ol;dihydrochloride Chemical compound Cl.Cl.C1CCCN1CC1(O)CCNCC1 UYSDJCZTLQZLKL-UHFFFAOYSA-N 0.000 description 1
- IZZIRCRFTNUPAB-UHFFFAOYSA-N 4-[[[1-[4-[[4-(4-fluorophenyl)pyrimidin-2-yl]amino]phenyl]sulfonylpiperidin-4-yl]-methylamino]methyl]-1,5-dimethylpyrrole-2-carbonitrile Chemical compound C1CN(S(=O)(=O)C=2C=CC(NC=3N=C(C=CN=3)C=3C=CC(F)=CC=3)=CC=2)CCC1N(C)CC=1C=C(C#N)N(C)C=1C IZZIRCRFTNUPAB-UHFFFAOYSA-N 0.000 description 1
- LWJLCKLFBPRYJA-UHFFFAOYSA-N 4-[[[1-[4-[[4-(4-fluorophenyl)pyrimidin-2-yl]amino]phenyl]sulfonylpiperidin-4-yl]-methylamino]methyl]-3,5-dimethyl-1h-pyrrole-2-carbonitrile Chemical compound C1CN(S(=O)(=O)C=2C=CC(NC=3N=C(C=CN=3)C=3C=CC(F)=CC=3)=CC=2)CCC1N(C)CC1=C(C)NC(C#N)=C1C LWJLCKLFBPRYJA-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- XIQRLHSCQPTITP-UHFFFAOYSA-N 6-azabicyclo[3.2.1]octan-3-amine Chemical compound C1C(N)CC2CNC1C2 XIQRLHSCQPTITP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- XYUVTVGPYVVUCP-UHFFFAOYSA-N 9-azabicyclo[3.3.1]nonan-3-amine Chemical compound C1CCC2CC(N)CC1N2 XYUVTVGPYVVUCP-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229910014033 C-OH Inorganic materials 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- FZMGQJCMCGHTLE-UHFFFAOYSA-N FC(C1=CC=C(C=C1)B(O)O)(F)F.ClC1=C(C=C(C(=C1)Cl)F)B(O)O.FC=1C(=C(C=CC1)B(O)O)F Chemical compound FC(C1=CC=C(C=C1)B(O)O)(F)F.ClC1=C(C=C(C(=C1)Cl)F)B(O)O.FC=1C(=C(C=CC1)B(O)O)F FZMGQJCMCGHTLE-UHFFFAOYSA-N 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229940123414 Folate antagonist Drugs 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 108030005449 Polo kinases Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 102000000551 Syk Kinase Human genes 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- VNEMVKOXLBIWTB-UHFFFAOYSA-N aminomethyl benzoate Chemical group NCOC(=O)C1=CC=CC=C1 VNEMVKOXLBIWTB-UHFFFAOYSA-N 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- 239000003976 antineoplastic alkaloid Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000019664 bone resorption disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 125000002720 diazolyl group Chemical group 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004674 formic acids Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000005001 male reproductive tract Anatomy 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 208000029565 malignant colon neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 208000037843 metastatic solid tumor Diseases 0.000 description 1
- OPUAWDUYWRUIIL-UHFFFAOYSA-N methanedisulfonic acid Chemical compound OS(=O)(=O)CS(O)(=O)=O OPUAWDUYWRUIIL-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- LPWAKYISHIZIPO-UHFFFAOYSA-N morpholin-4-ylmethyl benzoate Chemical class C=1C=CC=CC=1C(=O)OCN1CCOCC1 LPWAKYISHIZIPO-UHFFFAOYSA-N 0.000 description 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- GKAAARZCNCAWFD-UHFFFAOYSA-N n,3-dimethyl-3-azabicyclo[3.2.1]octan-8-amine Chemical compound C1N(C)CC2CCC1C2NC GKAAARZCNCAWFD-UHFFFAOYSA-N 0.000 description 1
- MCBLHOQTOYYMRX-UHFFFAOYSA-N n,3-dimethyl-3-azabicyclo[3.3.1]nonan-9-amine Chemical compound C1CCC2CN(C)CC1C2NC MCBLHOQTOYYMRX-UHFFFAOYSA-N 0.000 description 1
- KWZHDTXZEQVPFR-UHFFFAOYSA-N n,6-dimethyl-6-azabicyclo[3.2.1]octan-3-amine Chemical compound C1C(NC)CC2CN(C)C1C2 KWZHDTXZEQVPFR-UHFFFAOYSA-N 0.000 description 1
- JIGPXLSSOWEMKY-UHFFFAOYSA-N n-(2-pyrrolidin-1-ylethyl)oxan-4-amine Chemical compound C1COCCC1NCCN1CCCC1 JIGPXLSSOWEMKY-UHFFFAOYSA-N 0.000 description 1
- GDFYLALOASTLIS-NRFANRHFSA-N n-[4-[4-[(r)-amino-(4-fluorophenyl)methyl]piperidin-1-yl]sulfonylphenyl]-4-chloropyrimidin-2-amine Chemical compound C1CC([C@@H](N)C=2C=CC(F)=CC=2)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=CC(Cl)=N1 GDFYLALOASTLIS-NRFANRHFSA-N 0.000 description 1
- DBVHLQNDRMTSTJ-UHFFFAOYSA-N n-[4-[4-[2,3-dihydro-1-benzofuran-5-ylmethyl(methyl)amino]piperidin-1-yl]sulfonylphenyl]-4-(4-fluorophenyl)pyrimidin-2-amine Chemical compound C=1C=C2OCCC2=CC=1CN(C)C(CC1)CCN1S(=O)(=O)C(C=C1)=CC=C1NC(N=1)=NC=CC=1C1=CC=C(F)C=C1 DBVHLQNDRMTSTJ-UHFFFAOYSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CCGKDXITQVRPNY-UHFFFAOYSA-N n-dianilinophosphinothioylaniline Chemical compound C=1C=CC=CC=1NP(NC=1C=CC=CC=1)(=S)NC1=CC=CC=C1 CCGKDXITQVRPNY-UHFFFAOYSA-N 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229940043138 pentosan polysulfate Drugs 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 230000006824 pyrimidine synthesis Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- ULSBMKGFFFMGOI-UHFFFAOYSA-N tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11OC1 ULSBMKGFFFMGOI-UHFFFAOYSA-N 0.000 description 1
- DVBRIIOYNCBOJD-UHFFFAOYSA-N tert-butyl 4-(2-pyrrolidin-1-ylethylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NCCN1CCCC1 DVBRIIOYNCBOJD-UHFFFAOYSA-N 0.000 description 1
- GTJLXWZRRAEFRL-UHFFFAOYSA-N tert-butyl 4-[[4-[(4-chloropyrimidin-2-yl)amino]phenyl]sulfonyl-methylamino]piperidine-1-carboxylate Chemical compound C=1C=C(NC=2N=C(Cl)C=CN=2)C=CC=1S(=O)(=O)N(C)C1CCN(C(=O)OC(C)(C)C)CC1 GTJLXWZRRAEFRL-UHFFFAOYSA-N 0.000 description 1
- DGTBDFMXAKMFPL-UHFFFAOYSA-N tert-butyl 4-[[4-[[4-(4-fluorophenyl)pyrimidin-2-yl]amino]phenyl]sulfonyl-methylamino]piperidine-1-carboxylate Chemical compound C=1C=C(NC=2N=C(C=CN=2)C=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(C)C1CCN(C(=O)OC(C)(C)C)CC1 DGTBDFMXAKMFPL-UHFFFAOYSA-N 0.000 description 1
- VEVACIOMNFRTID-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-(pyrrolidin-1-ylmethyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(O)CN1CCCC1 VEVACIOMNFRTID-UHFFFAOYSA-N 0.000 description 1
- SUKDOKZUWHKUGX-UHFFFAOYSA-N tert-butyl n-[1-[4-[(4-chloropyrimidin-2-yl)amino]phenyl]sulfonylpiperidin-4-yl]-n-methylcarbamate Chemical compound C1CC(N(C)C(=O)OC(C)(C)C)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=CC(Cl)=N1 SUKDOKZUWHKUGX-UHFFFAOYSA-N 0.000 description 1
- ALLHABXKHPMIEZ-UHFFFAOYSA-N tert-butyl n-[2-[(1-benzylpiperidin-4-yl)-[4-[(4-chloropyrimidin-2-yl)amino]phenyl]sulfonylamino]ethyl]carbamate Chemical compound C=1C=C(NC=2N=C(Cl)C=CN=2)C=CC=1S(=O)(=O)N(CCNC(=O)OC(C)(C)C)C(CC1)CCN1CC1=CC=CC=C1 ALLHABXKHPMIEZ-UHFFFAOYSA-N 0.000 description 1
- PXGKISYUKKMYIB-UHFFFAOYSA-N tert-butyl n-[2-[(1-benzylpiperidin-4-yl)amino]ethyl]carbamate Chemical compound C1CC(NCCNC(=O)OC(C)(C)C)CCN1CC1=CC=CC=C1 PXGKISYUKKMYIB-UHFFFAOYSA-N 0.000 description 1
- SBRKASPSUHXFCW-UHFFFAOYSA-N tert-butyl n-[2-[[4-[[4-(4-fluorophenyl)pyrimidin-2-yl]amino]phenyl]sulfonyl-piperidin-4-ylamino]ethyl]carbamate Chemical compound C=1C=C(NC=2N=C(C=CN=2)C=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCNC(=O)OC(C)(C)C)C1CCNCC1 SBRKASPSUHXFCW-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to novel phenyl- (4-phenyl-pyrimidin-2-yl) -amino derivatives, process for their preparation, the novel intermediates obtained, their use as medicaments, the pharmaceutical compositions containing them and the novel use thereof.
- pyrimidine derivatives such as pyrimidine derivatives.
- Patent WO200164654-A1 mentions 2, 4-di- (hetero) arylpyrimidines substituted in 5, inhibitors of CDK2 and FAK kinases, as well as other serine-threonine kinase and CDK inhibitory aminopyrimidines are presented in WO2003030909-A1.
- WO2004046118-A2 discloses 2,4-diphenylaminopyrimidine derivatives as inhibitors of cell proliferation.
- a series of 5-cyano-2-aminopyrimidines are presented as inhibitors of KDR and FGFR kinases, in WO200078731-A1, other pyrimidines as inhibitors of FAK and IGFR in WO2004080980A-1, and also ZAP-70, FAK and / or Syk tyrosine kinase in WO2003078404A1, and PLK polokinases in WO2004074244-A2, as cytostatic agents.
- the subject of the present invention is therefore new Phenyl- (4-phenyl-pyrimidin-2-yl) -amino derivatives having inhibitory effects on protein kinases.
- the products of the present invention can thus in particular be used for the prevention or treatment of conditions capable of being modulated by the inhibition of the activity of protein kinases.
- the protein kinase IKK-alpha (IKK ⁇ ) and IKK-beta (IKK ⁇ ) are more particularly mentioned.
- the compounds of the present invention are kinase inhibitors, in particular IKK-alpha and IKK-beta, therefore inhibit NF-KB (nuclear factor kappa B) activity, so they can be used in the treatment of prophylaxis and inflammatory diseases, in cancer and diabetes.
- kinase inhibitors in particular IKK-alpha and IKK-beta, therefore inhibit NF-KB (nuclear factor kappa B) activity, so they can be used in the treatment of prophylaxis and inflammatory diseases, in cancer and diabetes.
- NF-kB Nuclear factor kappa B
- NF-kB belongs to a family of transcription factor complexes consisting of different combinations of Rel / NF-KB polypeptides.
- Members of this family of NF- ⁇ B-related polypeptides regulate the expression of genes involved in immune and inflammatory responses. ((Bames PJ, Karin M (1997) N Engl J Med 336, 1066-1071) and (Baeuerle PA, Baichwal VR (1997) Adv Immunol 65, 111-137)).
- NF- ⁇ B dimers are retained in inactive form in the cytoplasm by inhibitory proteins members of the IKB family (Beg et al., Genes Dev., 7: 2064-2070, 1993; Morin, Trends Genet 9: 427-43) 3), 199 '); Haskil and. al., Cell 65: 1281-1289, 1991).
- the proteins of the IKB family mask the NF-KB nuclear translocation signal.
- IKB-Kinase complex IKB-Kinase complex
- IKK IKB-Kinase complex
- IKB will be subject to ubiquitination leading to its degradation by the proteasome (26S), thus allowing the release and translocation of NF- ⁇ B in the nucleus where it will bind to specific sequences at the level of the promoters of target genes thus inducing their transcription.
- IKK IKB-Kinase complex
- IKKa IKK1
- IKK2 IKK ⁇
- IKK2 IKK2 is the dominant kinase (Mercurio et al., Mol., Cell Biol., 19: 1526, 1999-, Zandi et al., Science, 28: 1, 3) 60, 1998; Lee and. al, Proe. Natl. Acad. Sci. USA 95:93) 19, 1998).
- NF-KB-regulated genes encode pro-inflammatory mediators, cytokines, cell adhesion molecules, and acute phase proteins, which in turn will induce activation of NF- ⁇ B by autocrine or paracrine mechanisms. Inhibition of NF- ⁇ B activation appears to be very important in the treatment of inflammatory diseases.
- NF-KB plays a role in the growth of normal cells but also malignant cells. Proteins produced by expression of NF- ⁇ B regulated genes include cytokines, chemokines, adhesion molecules, cell growth mediators, angiogenesis. In addition, various studies have shown that NF-KB plays an essential role in neoplastic transformations. For example NF- ⁇ B may be associated with cell transformation in vitro and in vivo following overexpression, amplification, rearrangement or translocation events (Mercurio, R, and Manning, AM (1999) Oncogene, 18: 6163- 6171). In some human lymphoid tumor cells, the genes encoding the different NF-KB members are rearranged or amplified.
- NF-KB can promote cell growth by inducing transcription of cyclin D, which associated with Rb hyperphosphorylation results in the transition of G1 to S phases and inhibition of apoptosis. It has been shown that in a large number of tumor cell lines, constitutive activity of NF- ⁇ B is found following the activation of IKK2. NF- ⁇ B is constitutively activated in Hodgkin's disease and the inhibition of NF- ⁇ B blocks the growth of these lymphomas. On the other hand, inhibition of NF- ⁇ B by expression of the I ⁇ B ⁇ repressor induces apoptosis of cells expressing the oncogenic H-Ras allele (Baldwin, J. Clin Invest, 107: 241 (2001), Bargou et al., J. Clin Invest, 100: 2961 (1997), Mayo et al., Science 178: 1812 (1997).
- NF-KB The constitutive activity of NF-KB seems to contribute to oncogenesis through the activation of several anti-apoptotic genes such as Al / Bfi-1, IEX-I, MAP, thus resulting in the suppression of the death pathway. cellular.
- NF-KB Through the activation of cyclin D, NF-KB can promote the growth of tumor cells.
- the regulation of adhesion molecules and surface proteases suggests a role for NF-KB signaling in metastases.
- NF-KB is involved in the induction of chemoresistance. NF-KB is activated in response to a number of chemotherapy treatments.
- R represents a hydrogen atom or a halogen atom
- R2, R3 and R4, which are identical or different, are chosen from hydrogen, halogen atoms, CN, CONH2, CONHaIk, CON (alk) 2, and the alkyl and alkoxy radicals themselves, if appropriate; substituted by one or more halogen atoms or a radical CN,
- R5 represents a hydrogen atom or a halogen atom
- Z represents CO or SO2; and the radical -N (D) (W) is such that:
- ring (Y) when Y represents RIO may contain a carbon bridge consisting of 1 to 3 carbons,
- R10 represents a hydrogen atom, a cycloalkyl radical or an alkyl, CH2-alkenyl or CH2-alkynyl radical, all optionally substituted with a naphthyl radical or with one or more identical or different radicals chosen from halogen atoms and hydroxyl, alkoxy, aryl and heteroaryl radicals, the alkyl radicals represented by RIO being furthermore optionally substituted by a hydroxyl radical, NR8R9, CONR8R9, phosphonate, alkylthio optionally oxidized to sulphone or heterocycloalkyl, all the aryl, heteroaryl and heterocycloalkyl radicals being optionally substituted; ;
- R1 and R6 substituted on the same carbon atom by R1 and R6, containing 4 to 7 members, being saturated and may additionally contain a carbon bridge consisting of 1 to 3 carbons, it being understood that R1 and R ⁇ represent one of the 6 - ⁇ alternatives following i) to vi): i) R1 represents -X1-R7 with X1 represents - (CH2) m- and R7 represents a heterocycloalkyl, aryl or heteroaryl ring, all optionally substituted; and R6 is hydrogen, or hydroxyl, methyl, methoxy, - (CH2) mOH, -CO-NRaRb, -CH2-NraRb, -CO2H, and -CO2alk;
- R1 represents -NRc-W with W represents the hydrogen atom or an alkyl radical containing from 1 to 4 linear or branched carbon atoms from 3 carbon atoms optionally substituted with a radical chosen from -PO (OEt ) 2, -OH, -OaIk, -CF3, -CO-NR8R9 and SO2-alk; and R6 represents hydrogen; it being understood that when W represents a hydrogen atom then z represents CO;
- R1 represents -CH2-NRc-W with W represents the hydrogen atom or an alkyl radical containing from 1 to 4 linear or branched carbon atoms from 3 carbon atoms and optionally substituted by a radical chosen from - PO (OEt) 2, -OH, -OEt, -CF3, -CO- N (alk) 2 and SO2-alk; and R6 represents hydrogen;
- R1 represents -CO-N (Rc) -OR 'c and R ⁇ represents hydrogen
- n, n1 and n2, identical or different, represent an integer of 0 to 3;
- m represents an integer of 1 to 3;
- Rc and R 'c identical or different, represent the hydrogen atom or an alkyl radical containing from 1 to 4 carbon atoms optionally substituted with one or more halogen atoms;
- R8 represents the hydrogen atom or the alkyl, cycloalkyl or heterocycloalkyl radicals themselves optionally substituted by one or more radicals chosen from halogen atoms and hydroxyl, alkoxy, NH 2, NHalkyl and N (alkyl) 2 radicals, -CONH2, -CONHalkyl or -CON (alkyl) 2, the alkyl radicals that R8 represents being further optionally substituted by a phosphonate radical, alkylthio optionally oxidized to sulfone or by an optionally substituted saturated or unsaturated aryl or heterocyclic radical;
- NR8R9 is such that either R8 and R9, which are identical or different, are chosen from the values of R8, ie R8 and R9 form, with the nitrogen atom to which they are bonded, a cyclic amine which may optionally contain one or two other heteroatoms chosen from O , S, N or NRc, the cyclic amine thus formed being itself optionally substituted; all the aryl, naphthyl, phenyl, heterocyclic, heterocycloalkyl and heteroaryl radicals above, as well as the cyclic amine which R8 and R9 can form with the nitrogen atom to which they are bound, being themselves optionally substituted by one or more identical or different radicals selected from halogen atoms; hydroxyl radicals; cyano; NR8R9; and the alkyl, cycloalkyl, alkoxy, phenyl, heterocycloalkyl and heteroaryl radicals, themselves optionally substituted by one or more identical or different radicals chosen from hal
- the subject of the present invention is the products of formula (I) as defined above in which R 2, R 3, R 4, R 5, Z and the radical -N (D) (W) have the meanings indicated in any one of the other claims and R represents an atom of halogen; said products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as addition salts with inorganic and organic acids of said products of formula
- the subject of the present invention is the products of formula (I) as defined above in which R2, R3, R4, R5, Z and the radical -N (D) (W) have the meanings indicated for any one of other claims and R represents a hydrogen atom; said products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as addition salts with inorganic and organic acids of said products of formula (I).
- R, R5, Z and the radical -N (D) (W) have the meanings indicated in any one of the other claims and R 2, R 3 and R 4, which are identical or different, are chosen from hydrogen atom, halogen atoms, CN radical and alkyl and alkoxy radicals, themselves optionally substituted by one or more halogen atoms or radical CN, CONH2, CONHaIk or CON (alk) 2, it being understood that one or two of R2, R3 and R4 represent a hydrogen atom or R2, R3 and R4 all represent methoxy; said products of formula (I) being in all isomeric forms possible racemic, enantiomers and diastereoisomers, as well as the addition salts with the inorganic and organic acids of said products of formula (D •
- the present invention relates in particular to the products of formula (I) as defined above or below in which R, R5, Z and the radical -N (D) (W) have the meanings indicated above or above.
- R2, R3, R4 are such that one of R2, R3 and R4 represents a CN or CH2-CN radical and the other two of R2, R3, R4 are selected from the other values defined for these radicals, ie hydrogen atom, halogen atoms, CN, CONH2, CONHaIk, CON (alk) 2 radical, and alkyl and alkoxy radicals, themselves optionally substituted by one or more halogen atoms or a CN radical, CONH2, CONHaIk, CON (alk) 2, OH or OCH3, it being understood that one or two of R2, R3 and R4 represent a hydrogen atom, said products of formula (I) being in all possible isomeric forms racemic, enantiomers and diastereoisomers, as well as the addition salts with the mineral and
- R has the meaning indicated above or below
- R 2, R 3 and R 4 which are identical or different, are such that one represents a halogen atom or CF 3 and the other two, which are identical or different, represent a hydrogen atom or a halogen atom or an alkyl radical or alkoxy optionally substituted by one or more halogen atoms;
- R5 represents a hydrogen atom or a halogen atom
- Z represents CO or SO2; and the radical -N (D) (W) is such that:
- RIO may contain a carbon bridge consisting of 1 to 3 carbons
- R10 represents the hydrogen atom, a cycloalkyl radical or an alkyl radical, CH2-alkenyl or CH2-alkynyl, all optionally substituted by a naphthyl radical or by one or a plurality of identical or different radicals chosen from halogen atoms and hydroxyl, alkoxy, aryl and heteroaryl radicals, the alkyl radicals represented by RIO being furthermore optionally substituted by a hydroxyl radical, NR8R9, CONR8R9, phosphonate or alkylthio optionally oxidized to sulphone or heterocycloalkyl, all aryl, heteroaryl and heterocycloalkyl radicals being optionally substituted; b) W and D form with the nitrogen atom to which they are attached a ring (N)
- R1 and R6 substituted on the same carbon atom by R1 and R6, containing 4 to 7 members, being saturated and may additionally contain a carbon bridge consisting of 1 to 3 carbons, it being understood that R1 and R6 represent one of the following 5 alternatives i ) to v): i) R1 represents -X1-R7 with X1 represents - (CH2) m- and R7 represents a heterocycloalkyl, aryl or heteroaryl ring, all optionally substituted; and R6 represents hydrogen atom or hydroxyl radicals, - (CH2) mOH, -CO-NRaRb, -CH2-NRaRb and, -CO2H, - CO2alk;
- R1 represents -NRc-W with W represents the hydrogen atom or an alkyl radical containing from 1 to 4 linear or branched carbon atoms from 3 carbon atoms optionally substituted with a radical chosen from -PO (OEt ) 2, -OH, -OaIk, -CF3, -CO-NR8R9 and SO2-alk; and R6 represents hydrogen; it being understood that when W represents a hydrogen atom then z represents CO; iv) R1 represents -CH2-NRc-W with W represents the hydrogen atom or an alkyl radical containing from 1 to 4 linear or branched carbon atoms from 3 carbon atoms and optionally substituted by a radical chosen from - PO (OEt) 2, -OH, -OEt, -CF3, -CO- N (alk) 2 and SO2-alk; and R6 represents hydrogen;
- R1 represents -CO-N (Rc) -OR 'c and R6 represents hydrogen
- n, n1 and n2, identical or different, represent an integer of 0 to 3;
- m represents an integer of 1 to 3;
- Rc and R 'c identical or different, represent the hydrogen atom or an alkyl radical containing from 1 to 4 carbon atoms optionally substituted with one or more halogen atoms;
- R8 represents the hydrogen atom or the alkyl, cycloalkyl or heterocycloalkyl radicals themselves optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, alkoxy and NH 2 radicals,
- alkyl radicals represented by R8 being furthermore optionally substituted with a phosphonate, alkylthio radical optionally oxed to sulphone or with an optionally substituted saturated or unsaturated aryl or heterocyclic radical;
- NR8R9 is such that either R8 and R9, which are identical or different, are chosen from the values of R8, ie R8 and R9 form, with the nitrogen atom to which they are bonded, a cyclic amine which may optionally contain one or two other heteroatoms chosen from 0 , S, N or NRc, the cyclic amine thus formed being itself optionally substituted; all the aryl, naphthyl and phenyl radicals, heterocyclic, heterocycloalkyl and heteroaryl compounds as well as the cyclic amine which R8 and R9 can form with the nitrogen atom to which they are attached being themselves optionally substituted by one or more identical or different radicals chosen from the atoms of 'halogen; hydroxyl radicals; cyano; NR8R9; and the alkyl, cycloalkyl, alkoxy, phenyl, heterocycloalkyl and heteroaryl radicals, themselves optionally substituted by one or more identical or different radicals chosen from
- NRaRb is such that either Ra and Rb, which may be identical or different, represent a hydrogen atom or an alkyl radical containing from 1 to 4 carbon atoms or a cycloalkyl radical, these alkyl and cycloalkyl radicals being optionally substituted with one or more radicals; identical or different selected from halogen atoms and hydroxyl, alkoxy, NH 2, NHalkyl and N (alkyl) 2 radicals; either Ra and Rb form, with the nitrogen atom to which they are bonded, a cyclic amine which may optionally contain one or two other heteroatoms chosen from O, S, N or NRc, the cyclic amine thus formed being itself optionally substituted by one or more identical or different radicals chosen from halogen atoms and alkyl radicals themselves optionally substituted with one or more halogen atoms;
- the present invention thus relates in particular to the products of formula (I) as defined above corresponding to formula (IA) in which R, R2, R3, R4,
- R5, Z and D are selected from the meaning indicated above or hereafter and ring (Y) may be chosen from any one of the following values: - When ring (Y) is such that Y represents C-OH, CF2
- the ring formed can in particular be a cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl and particularly a cyclohexyl, these radicals therefore being substituted especially in para respectively by OH, 2 F, the radical OR8 or the radical NR8R9 in which R8 and R9 are selected from the meanings defined above.
- ring (Y) When ring (Y) is such that Y represents NR10, the ring formed may in particular be an azetidinyl, pyrrolidinyl or piperidinyl radical with the N atom in para or meta, which therefore bears the substituent RIO as defined herein.
- RIO substituent RIO as defined herein.
- ring (Y) may represent a pyrrolidinyl or piperidinyl radical optionally substituted on the nitrogen atom by RIO which may represent an alkyl radical optionally substituted by a hydroxyl radical, -NR8R9, -CO-NR8R9, phosphonate, or alkylthio optionally oxidized to sulfone;
- the ring formed can in particular be the 8-azabicyclo (3, 2, 1) octanoyl ring or a ring selected from N, 9-dimethyl-9-azabicyclo [3.3.1] nonan-3-yl, N, 6-dimethyl-6-azabicyclo [3.2.1] octan-3-yl, N, 3-dimethyl 3-azabicyclo [3.2.1] octan-8yl or else N, 3-dimethyl-3-azabicyclo [3.3.1] nonan-9-yl.
- the ring (Y) formed can in particular be a bicyclic radical such as for example quinolizinyl or indolizinyl.
- the ring formed can in particular be a tetrahydrothiopyranyl or a tetrahydrothiophene: when ring (Y) is such that Y represents SO 2, the ring formed can in particular be a dioxidotetrahydro-3-thiophene.
- the ring formed can in particular be a tetrahydrofuran or tetrahydropyran.
- the ring formed can in particular be dioxaspiro (4,5) dec-8-yl.
- Y represents -NR10 with R10 represents cycloalkyl such as in particular cyclopropyl
- Y represents -NR 10 with R 10 represents an alkyl radical, in particular CH 3, C 2 H 5 or C 3 H 7 substituted with a phosphonate
- Y represents -NR 10 with R 10 represents an alkyl radical, in particular CH 3, C 2 H 5 or C 3 H 7 substituted with an alkylthio such as S-CH 3 or S-C 2 H 5 with S, optionally oxidized to sulphone, to form, for example, SO 2 -CH 3 or SO2-C2H5;
- Y represents -NR10 with R10 represents alkyl such as in particular CH3 or C2H5 substituted with one or more radicals chosen from halogen atoms such as F, and phenyl radicals and mono or bicyclic heterocycle, phenyl and heterocycle themselves optionally substituted by one or more radicals chosen from halogen atoms and alkyl, alkoxy, OH, CN, CF3, NH2, NHaIk and N (alk) 2 radicals: among these heterocycles which may be R10 may be mentioned in particular 5-membered unsaturated heterocycles containing one to four heteroatoms chosen from N, O and S: thus RIO can represent in particular the radicals -CH2-thienyl, -CH2-thiazolyl (N, S) , -CH2-thiadiazolyl (N, N, S), -CH2-furanyl (O), -CH2-pyrazolyl (N, N), -CH2-isoxazolyl
- RIO may also carry heterocycles as defined above such as pyridinyl radicals (with N of pyridine at 3 different positions); 2,3-Dihydro-1H-indolyl; quinolyl; isoquinolyl; pyrimidinyl; 2,3-Dihydro-benzofuranyl;
- Y represents CH-NR8R9 with NR8R9 such that R8 represents a hydrogen atom or an alkyl radical such as in particular CH3 and R9 represents a linear or branched alkyl radical such as in particular CH3, C2H5 or -CH2- or -CH (CH3) - or -CH (CH3) -CH2- substituted with either an optionally substituted saturated mono- or bicyclic heterocycle or an optionally substituted phenyl radical.
- heterocycles carried by R9 mention may be made especially of the following radicals: pyridine (with N of pyridine at 3 different positions); 2,3-Dihydro-1H-indolyl; quinolyl; isoquinolyl; pyrimidinyl; 2,3-Dihydro-benzofuranyl;
- Such heterocycles are optionally substituted with one or more radicals as defined above or hereinafter.
- the present invention thus relates in particular to the products of formula (I) as defined above corresponding to formula (IA) in which R, R2, R3, R4, R5 and Z and ring (Y) are chosen from the indicated meanings.
- D can be chosen from any one of the following values: D represents a hydrogen atom or an alkyl radical containing from 1 to 6 linear or branched carbon atoms optionally substituted by an NH 2 radical; , NHaIk, N (alk) 2 or with a saturated or unsaturated heterocycle, preferably a 5- or 6-membered monocycle as defined above and optionally substituted as indicated above or hereinafter;
- D represents a hydrogen atom or an alkyl radical containing from 1 to 5 linear or branched carbon atoms optionally substituted with NH 2 or else D represents this alkyl radical substituted with a saturated or unsaturated, preferably monocyclic, 5-membered heterocycle, itself optionally substituted as indicated above or below,
- ring (Y) represents a cyclohexyl radical substituted by an NR8R9 radical as defined above
- D represents a CH3 radical optionally substituted with a saturated or unsaturated heterocycle as defined above and R10 represents a CH3 radical;
- - D represents a hydrogen atom or a CH3 radical and ring (Y) represents a piperidine or a 8-azabicyclo (3,2,1) octan-3yl ring substituted on their nitrogen atom by RIO with RIO as defined above. More precisely :
- D represents alkenyl (3C) radicals such as allyl or alkynyl (3C) such as propargyl
- - D represents alkyl and in particular CH3, C2H5, C3H7 substituted with one or more identical or different radicals chosen from halogen atoms and NH2, NH (alk), N (alk) 2, NH-CH2-CH2OH, NH radicals; -CH2-C3H7-OH, NH (CH2-CF3), alkoxy, OH, or a saturated heterocycle such as for example pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl or an unsaturated heterocycle such as in particular those defined above for RIO.
- a saturated heterocycle such as for example pyrrolidinyl, piperidinyl, morpholinyl, tetrahydrofuranyl or an unsaturated heterocycle such as in particular those defined above for RIO.
- the subject of the present invention is thus the products of as defined above or hereafter corresponding to the formula (IA) in which R, R2, R3, R4, R5 and z have the meanings indicated above or above.
- D represents a hydrogen atom or an alkyl radical containing from 1 to 4 linear or branched carbon atoms optionally substituted with NH 2 and in particular CH 3 and ring (Y) is such that Y represents NR 10 with R 10 represents an alkyl radical containing from 1 to 6 atoms of linear or branched carbon optionally substituted by a radical chosen from halogen atoms and hydroxyl, phosphonate, sulphone, phenyl and heterocyclic radicals which are saturated or unsaturated monocyclic or bicyclic, these phenyl and heterocyclic radicals being themselves optionally substituted as indicated ci above or below, said products of formula (I) being in all the possible isomeric forms racemic, enantiomers and diastereoisomers, as well as the addition salt
- D represents an alkyl radical containing from 1 to 4 linear or branched carbon atoms optionally substituted with NH 2 and in particular CH 3 and ring (Y) is such that Y represents NR 8 R 9 in which R 8 represents a hydrogen atom or an alkyl radical and R 9 represents an alkyl radical containing from 1 to 6 linear or branched carbon atoms optionally substituted by a radical chosen from halogen atoms and hydroxyl, phosphonate, sulphone, phenyl and heterocyclic radicals which are saturated or unsaturated monocyclic or bicyclic, these phenyl and heterocyclic radicals; being themselves optionally substituted as indicated above or hereafter, said products of formula (I) being in all the possible isomeric forms racemic, enantiomers and diastereoisomers, as well as the addition salts with the mineral and organic acids of said products of formula (I).
- R, R1, R2, R3, R4, R5, R6, Z and ring (N) have the meanings given above or hereafter, said products of formula (I) being in all possible racemic isomeric forms, enantiomers and diastereoisomers, as well as the addition salts with the mineral and organic acids of said products of formula (I).
- the subject of the present invention is thus the products of formula (I) corresponding to formula (IB) as defined above or below, in which R, R2, R3 and R4, which are identical or different, are such that one represents a halogen atom or CF3 and the other two, identical or different, represent a hydrogen atom or a halogen atom or an alkyl radical or an alkoxy radical optionally substituted with one or more halogen atoms; R5 represents a hydrogen atom or a halogen atom;
- R1 and R6 being substituted on the same carbon atom by R1 and R6, containing 4 to 7 members, being saturated and may additionally contain a carbon bridge consisting of 1 with 3 carbons, with R 1 and R 6 as defined above or below,
- R1 and R6 are such that R1 represents -X1-R7 with X1 represents - (CH2) m- and R7 represents a heterocycloalkyl, aryl or heteroaryl ring, all optionally substituted; and R6 represents hydrogen atom or hydroxyl radicals, - (CH2) mOH, -CO-NRaRb, -CH2-NRaRb -CO2H, and -
- R1 represents -NRc-W with W represents the hydrogen atom or an alkyl radical containing from 1 to 4 linear or branched carbon atoms from 3 carbon atoms optionally substituted with a radical chosen from -PO (OEt) 2, -OH, -OaIk, -CF3, -CO-NR8R9 and SO2-alk and R6 represents hydrogen, it being understood that when W represents a hydrogen atom then z represents CO; or R1 represents -CH2-NRc-W with W represents the hydrogen atom or an alkyl radical containing from 1 to 4 linear or branched carbon atoms from 3 carbon atoms and optionally substituted with a radical chosen from -PO (OEt) 2, -OH, -OEt,
- the ring formed can in particular be the 8 aza bicyclo (3.2, l) oct 3 yl) or a ring selected from the following: 9-azabicyclo [3.3.1] nonan-3-yl, 6-azabicyclo [3.2.1] octan-3-yl, 3-azabicyclo [3.2] .1] octan-8yl or else 3-azabicyclo [3.3.1] nonan-9-yl.
- halogen denotes the fluorine, chlorine, bromine or iodine atoms and preferably fluorine, chlorine or bromine;
- alkyl radical denotes a linear or branched radical containing at most 6 carbon atoms and especially the methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl or isopentyl radicals; pentyl, tert-pentyl, neopentyl, hexyl, isohexyl, sec-hexyl, tert-hexyl and their linear or branched positional isomers;
- hydroxyalkyl radical denotes the alkyl radicals indicated above substituted by one or more hydroxyl radicals;
- alkenyl radical denotes a linear or branched radical containing at most 6 carbon atoms and preferentially 4 carbon atoms chosen for example from the following values: ethenyl or vinyl, propenyl or allyl, 1-propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl and hexenyl, as well as their linear or branched positional isomers: among the alkenyl values, mention is made more particularly of allyl or butenyl values.
- alkynyl radical denotes a linear or branched radical containing at most 6 carbon atoms and preferably 4 carbon atoms chosen, for example, from the following values: ethynyl, propynyl or propargyl, butynyl, n-butynyl, i-butynyl, 3- methylbut-2-ynyl, pentynyl or hexynyl and their linear or branched positional isomers: among the alkynyl values, the propargyl value is more particularly mentioned.
- alkylene radical denotes a linear or branched divalent radical containing at most 6 carbon atoms, derived from the alkyl radical above and thus chosen for example from the methylene, ethylene, propylene, isopropylene, butylene, isobutylene or sec-butylene radicals; pentylene;
- alkoxy radical denotes a linear or branched radical containing at most 6 carbon atoms chosen, for example, from methoxy, ethoxy, propoxy, isopropoxy, linear butoxy, secondary or tertiary, pentoxy, hexoxy and heptoxy radicals, and also their positional isomers; linear or branched;
- cycloalkyl radical denotes a monocyclic or bicyclic carbocyclic radical containing from 3 to 7 ring members and in particular denotes the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl radicals;
- aryl radical refers to unsaturated, monocyclic or fused carbocyclic ring radicals.
- examples of such an aryl radical include, in particular, phenyl or naphthyl radicals;
- heterocyclic radical denotes a radical saturated (heterocycloalkyl) or partially or completely unsaturated carbocylic acid (heteroaryl) comprising from 4 to 10 members interrupted by one or three heteroatoms, which may be identical or different, chosen from oxygen, nitrogen or sulfur atoms: from the heteroaryl radicals to 5-membered radicals which may be mentioned in particular are radicals containing one to four heteroatoms selected from optionally oxidized N, O and optionally oxidized S, such as the radicals, for example thienyl radicals such as 2-thienyl, 3-thienyl or dioxidothienyl, thiazolyl (N, S), furyl (O), 2-furyl, pyrrolyl (NH, NCH3), isothiazolyl
- 6-membered heteroaryl radicals include, in particular, pyridyl radicals such as 2-pyridyl, 3-pyridyl and 4-pyridyl, pyridyl N-oxide, pyrimidinyl, pyridazinyl and pyrazinyl radicals; among the fused heteroaryl radicals containing at least one heteroatom chosen from sulfur, nitrogen and oxygen, mention may be made, for example, of benzothienyl, benzofuryl, benzofuranyl, benzoxazolyl, indazolyl, indolyl, indolinyl, indolinonyl, quinolyl and isoquinolyl radicals, azaindolyl, benzimidazolyl, benzothiazolyl, naphth
- heterocycloalkyl saturated
- heterocycloalkyl saturated
- heterocycloalkyl saturated
- heterocycloalkyl saturated
- alkylamino radical or NH (alk) radical and dialkylamino radical or N (alk) 2 denotes NH 2 amino radicals substituted respectively by one or two linear or branched alkyl radicals, which are identical or different in the case of dialkylamino, chosen from alkyl radicals as defined above and optionally substituted as indicated above or below: mention may be made, for example, of methylamino, ethylamino, propylamino or butylamino radicals, and dimethylamino, diethylamino and methylethylamino radicals.
- cycloalkylamino thus denotes an amino radical substituted in particular by a cycloalkyl radical chosen from the radicals defined above: there may thus be mentioned, for example, the cyclopropylamino, cyclobutylamino or cyclopentylamino radicals; still cyclohexylamino.
- cyclic amine denotes a monocyclic or bicyclic radical containing from 3 to 10 members in which at least one carbon atom is replaced by a nitrogen atom, this cyclic radical possibly also containing one or more other heteroatoms chosen from O, S, SO 2, N or NRc with Rc as defined above:
- cyclic amines include, for example, pyrrolyl, piperidyl, morpholinyl, piperazinyl, pyrrolidinyl, azetidinyl.
- patient refers to humans but also other mammals.
- Prodrug refers to a product that can be converted in vivo by metabolic mechanisms (such as hydrolysis) into a product of formula (I).
- an ester of a product of formula (I) containing a hydroxyl group can be converted by in vivo hydrolysis to its parent molecule.
- hydroxyl group-containing esters of the formula (I) such as acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene bisulfates and the like.
- hydroxyl-containing products of the formula (I) can be prepared from acidic residues such as those described by Bundgaard et al. al., J. Med. Chem.
- esters include especially (Aminomethyl) -benzoates substituted, dialkylamino-methylbenzoates wherein the two alkyl groups can be bonded together or can be interrupted by an oxygen atom or by an optionally substituted nitrogen atom or an alkylated nitrogen atom or morpholino methyl) benzoates, eg 3- or 4-
- the addition salts with the inorganic or organic acids of the products of formula (I) can be, for example, the salts formed with hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, propionic, acetic, trifluoroacetic, formic acids, benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic, glyoxylic, aspartic, ascorbic, alkylmonosulphonic acids such as, for example, methanesulfonic acid, ethanesulphonic acid, propanesulphonic acid, alkylsulphonic acids such as, for example, methanedisulfonic acid, alpha, beta-ethanedisulfonic acid, arylmonosulfonic acids such as benzenesulphonic acid and aryldisulphonic acids.
- stereoisomerism can be defined in its broad sense as the isomerism of compounds having the same developed formulas, but whose different groups are arranged differently in space, such as in particular in monosubstituted cyclohexanes whose substituent can be in axial or equatorial position.
- stereoisomerism due to the different spatial arrangements of fixed substituents, either on double bonds or on rings, often called E / Z geometrical isomerism or cis-trans or diastereoisomeric isomerism.
- stereoisomer is used in the present application in its broadest sense and therefore relates to all of the compounds indicated above.
- R has the meaning indicated above or below, R2, R3 and R4, identical or different, are such that one represents a halogen atom or CF3 and the other two, identical or different, represent a hydrogen atom; hydrogen, a halogen atom or an alkyl or alkoxy radical optionally substituted with one or more halogen atoms;
- R5 represents a hydrogen atom or a halogen atom
- D represents a hydrogen atom, a cycloalkyl radical or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms, OR 8 and NR 8 R 9
- R10 represents a hydrogen atom or an alkyl radical optionally substituted with one or more identical or different radicals chosen from halogen atoms and hydroxyl, alkoxy, phenyl and heteroaryl radicals, the phenyl and heteroaryl radicals being themselves optionally substituted with one or more identical or different radicals chosen from halogen atoms and
- R8 represents the hydrogen atom, linear or branched alkyl radicals containing at most 4 carbon atoms or cycloalkyl radicals containing from 3 to 6 members, alkyl and cycloalkyl themselves optionally substituted by one or more identical or different radicals chosen; among halogen atoms and hydroxyl radicals, NH2, NHaIk and N (alk) 2;
- NR8R9 is such that either R8 and R9, which are identical or different, are chosen from the values of R8, ie R8 and R9 form, with the nitrogen atom to which they are bonded, a cyclic amine chosen from the pyrrolyl, piperidyl and morpholinyl radicals, pyrrolidinyl, azetidinyl and piperazinyl optionally substituted on the optional second atom by an alkyl radical itself optionally substituted with one or more identical or different radicals chosen from halogen atoms and the hydroxyl radical; said products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as addition salts with inorganic and organic acids of said products of formula (I).
- the ring containing Y may consist of 4 to 7 members, and saturated with Y representing an oxygen atom 0, a sulfur atom S optionally oxidized with or two oxygen atoms or a radical chosen from N-R7, CH-NH2, CH-NHaIk or CH-N (alk) 2, with R7 as defined above or hereinafter.
- R has the meaning indicated above or below
- R2, R3 and R4, which are identical or different, are such that one represents a fluorine or chlorine atom or CF3 and the other two, which are identical or different, represent the hydrogen atom, a fluorine or chlorine atom; or a methyl or methoxy radical optionally substituted by one or more fluorine atoms;
- R5 represents a hydrogen atom or a fluorine or chlorine atom
- Z represents SO2 or CO
- D represents a hydrogen atom or a cyclopropyl, methyl, ethyl, propyl or butyl radical optionally substituted with one or more identical or different radicals chosen from the fluorine atom and the hydroxyl, amino, alkylamino, dialkylamino and piperidinyl radicals, morpholinyl, azetidinyl, piperazinyl, pyrrolidinyl and pyrrolyl;
- the ring (Y) is selected from cyclohexyl radicals itself optionally substituted by amino; tetrahydropyran; dioxidothiényle; and the pyrrolidinyl, piperidinyl and azepinyl radicals optionally substituted on their nitrogen atom with a methyl, propyl, butyl, isopropyl, isobutyl, isopentyl or ethyl radical, themselves optionally substituted with one or more radicals chosen from halogen atoms; hydroxyl radicals and phenyl quinolyl radicals, pyridyl optionally oxidized on its nitrogen atom, thienyl, thiazolyl, thiadiazolyl, tetrazolyl, pyrazinyl, furyl and imidazolyl, the latter cyclic radicals being themselves optionally substituted with one or more idnetic or different radicals chosen from halogen atoms and hydroxyl, methyl
- R has the meaning indicated above or below, R2, R3 and R4, identical or different, are such that one represents a fluorine atom or CF3 and the other two, identical or different, represent the hydrogen atom, a fluorine or chlorine atom or a methyl radical; R5 represents a hydrogen atom;
- D represents a methyl radical; or an ethyl radical, optionally substituted by an amino, alkylamino, dialkylamino or pyrrolidinyl radical;
- the ring containing Y represents a cyclohexyl radical, itself optionally substituted with amino, or a piperidinyl radical optionally substituted on its nitrogen atom by a methyl, propyl, butyl, isopropyl, isobutyl, isopentyl or ethyl radical, themselves optionally substituted with one or more halogen atoms or a radical chosen from hydroxyl; thiadiazolyl; tetrazolyl; phenyl itself optionally substituted with halogen; quinolyl; pyridyl optionally oxidized on its nitrogen atom; furyl; and imidazolyl itself optionally substituted with alkyl; said products of formula (I) being in all isomeric forms possible racemic, enantiomers and diastere
- NR8R9 does not form a cyclic amine
- NR8R9 is such that R8 represents a hydrogen atom or an alkyl radical and R9 is chosen from the set of values defined for R8.
- the radical NR8R9 may also represent the values defined above for NRaRb.
- R2, R3, R4 is alkoxy, methoxy is preferred.
- R has the meaning indicated above or below, R2, R3 and R4, which are identical or different, are such that one represents a fluorine atom and the other two, which are identical or different, represent the hydrogen atom, a fluorine or chlorine atom or a methyl radical; R5 represents a hydrogen atom;
- D represents a hydrogen atom or a methyl radical or an ethyl radical optionally substituted with NH 2;
- the cycle (Y) is chosen from the radicals tetrahydropyranyl, dioxidothienyl and pyrrolidinyl, piperidinyl and azepinyl radicals optionally substituted on their nitrogen atom (in 2 or 3 of the ring) with a methyl or ethyl, propyl or butyl radical, themselves optionally substituted with one or more halogen atoms or a phenyl, pyridyl, thienyl, or thiazolyl, thiadiazolyl, pyrazinyl, furyl or imidazolyl radical; said products of formula (I) being in all isomeric forms possible racemic, enantiomers and diastereoisomers, as well as the addition salts with the mineral and organic acids of said products of formula (D
- the subject of the present invention is in particular the products of formula (I) as defined above or hereafter corresponding to formula (IB) in which R 2, R 3, R 4, R 5 and Z have the meanings indicated above or hereinafter and the ring (N) represents one of the rings defined below: an azetidinyl or pyrrolidinyl ring substituted at the 3-position by R 1 and R 6 as defined above or hereinafter; a piperidinyl and azepinyl ring substituted in position 3 or 4 by R 1 and R 6 as defined above or hereinafter; an 8-aza bicyclo (3,2,1) octan-3-yl, 6-azabicyclo [3.2.1] octan-3-yl or 3-azabicyclo [3.2.1] octan-8-yl ring; said products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as addition salts with inorganic and organic acids of said products of formula
- the subject of the present invention is in particular the products of formula (I) as defined above or below. having the formula (IB) in which R, R2, R3, R4, R5 and Z have the meanings given above or hereafter and the ring (N) represents a pyrrolidinyl ring substituted at 3 by R1 and R ⁇ such that defined above or hereinafter or a piperidinyl ring substituted at the 3 or 4 position by R 1 and R ⁇ as defined above or below, said products of formula (I) being in all the possible isomeric forms racemic, enantiomers and diastereoisomers, as well as the addition salts with the mineral and organic acids of said products of formula (D
- R 2, R 3 and R 4 which are identical or different, are such that one represents a halogen atom or CF 3 and the other two, which are identical or different, represent a hydrogen atom or a halogen atom or an alkyl radical or an alkoxy radical optionally substituted with one or more halogen atoms;
- R5 represents a hydrogen atom or a halogen atom
- Z represents CO or SO2
- cycle (N) is
- R 1 and R 6 represent one of the following alternatives i) to v) i) R 1 represents -X 1 -R 7 with X 1 represents -CH 2 and R 7 represents a heterocycloalkyl, phenyl or heteroaryl, all optionally substituted; and R6 represents hydrogen atom or hydroxyl radicals, -CH2OH, -CO-NRaRb and -CO2Et;
- R1 represents -X2-R7 with X2 represents:
- R7 represents a heterocycloalkyl, phenyl or heteroaryl ring, all optionally substituted, and R ⁇ represents hydrogen;
- R1 represents -NRc-W with W represents the hydrogen atom or an alkyl radical containing from 1 to 4 linear or branched carbon atoms optionally substituted with a radical chosen from -PO (OEt) 2, -OH, - OEt, -CF3, -CO-NR8R9 and SO2-alk; and R6 represents hydrogen; it being understood that when W represents a hydrogen atom then z represents CO;
- R1 represents -CH2-NRc-W with W represents the hydrogen atom or an alkyl radical containing from 1 to 4 linear or branched carbon atoms from 3 carbon atoms and optionally substituted by a radical SO2-alk ; and R ⁇ represents hydrogen;
- R1 represents -CO-N (Rc) -OR 'c and R ⁇ represents hydrogen
- n, n1 and n2, identical or different, represent an integer of 0 to 2;
- Rc and R 'c identical or different represent the hydrogen atom or an alkyl radical containing 1 to 2 carbon atoms
- NRaRb is such that either Ra and Rb, identical or different, represent the hydrogen atom or a an alkyl radical containing from 1 to 4 carbon atoms optionally substituted with one or more identical or different radicals chosen from halogen atoms and hydroxyl, alkoxy, NH 2, NHalkyl and N (alkyl) 2 radicals; or Ra and Rb form with the nitrogen atom to which they are bonded a morpholinyl or pyrrolidinyl radical optionally substituted with one or more identical or different radicals chosen from halogen atoms and the alkyl radicals themselves optionally substituted with one or several halogen atoms; all the heterocycloalkyl, phenyl and heteroaryl radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms; hydroxyl radicals; cyan
- NR8R9 is such that either R8 and R9, which are identical or different, are such that R8 represents a hydrogen atom, a linear or branched alkyl radical containing at most 4 carbon atoms or a cycloalkyl radical containing from 3 to 6 ring members, alkyl and cycloalkyl themselves optionally substituted by one or more halogen atoms or a hydroxyl radical; and R 9 represents the hydrogen atom or an alkyl radical optionally substituted with one or more identical or different radicals chosen from halogen atoms and hydroxyl, alkoxy, NH 2, NHalkyl, N (alkyl) 2, phenyl or heterocycloalkyl radicals; or heteroaryl themselves optionally substituted with one or more radicals selected from halogen atoms and hydroxyl radical radicals, OCH3, CH3, -CH2OH, CN, CF3, OCF3, NH2, NHaIk or N (alk) 2; or R8 and R9 form
- all the heterocycloalkyl, phenyl and heteroaryl radicals that R7 represents may in particular be optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms; NR8R9 radicals; and the alkyl, cycloalkyl, alkoxy, phenyl, heterocycloalkyl and heteroaryl radicals, themselves optionally substituted by one or more identical or different radicals chosen from halogen atoms and hydroxyl, alkoxy, OCF3, CH3, -CH2OH, CN radicals; , CF3, OCF3, NH2, NHaIk, N (alk) 2, pyrrolidinyl, piperidinyl or
- R1, R2, R3, R4, R5, Z and the ring (N) have the meanings indicated above or below and R1 and R6 are such that: either R1 represents -X-R7 with X1 represents -CH2- and R6 represents the hydrogen atom or hydroxyl radicals, CH 2 -OH; -CO-N (CH3) 2, -CO-NHCH3, -CO-NH- (CH2) 2-N (CH3) 2 and -CO2Et; or R1 represents -X2-R7 with X represents:
- R6 represents hydrogen
- R7 is selected from pyrrolidinyl, piperidinyl, piperazinyl, pyrimidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuran, hexaydrofuranyl, phenyl, pyridyl, thienyl, thiazolyl, dithiazolyl, pyrazolyl, pyrazinyl, furyl, imidazolyl, pyrrolyl, oxazolyl, isoxazolyl, benzofuranyl, benzodihydrofuranyl and , benzoxodiazolyl, benzothiodiazolyl, benzothienyl, quinolyl, isoquinolyl
- R1 is -X1-R7 with X1 is -CH2- and R6 is hydrogen or hydroxyl, CH2-OH; -CO-N (CH3) 2, -CO-NHCH3, -CO-NH- (CH2) 2-N (CH3) 2 and -CO2Et; or R1 represents -X2-R7 with X2 represents: -O-, -CHOH-, -CH (OH) -CH2-, -CO-, -CHNH2-, -NH-CH2-, -N (CH3) -CH2- and CH 2 -NH-CH 2 -; and R6 represents hydrogen;
- R7 is selected from pyrrolidinyl, piperidinyl, piperazinyl, pyrimidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, phenyl, pyridyl, thienyl, thiazolyl, dithiazolyl, pyrazolyl, pyrazinyl, furyl, imidazolyl, pyrrolyl, oxazolyl, isoxazolyl, benzodihydrofuranyl, benzoxodiazolyl, benzothiodiazolyl and benzothienyl, quinolyl, isoquinolyl; all of these radicals represented by R7 being optionally substituted with one or more identical or different radicals chosen from halogen atoms and hydroxyl, methyl, methoxy, hydroxymethyl, alkoxymethyl, cyano, NH2, NHaIk, N (alk) 2, - radicals; CH2-NH2, -
- the subject of the present invention is in particular the products of formula (I) as defined above or below.
- R, R 1, R 5, R 6, Z, D, W, ring (Y) and ring (N) have the meanings given above or hereafter;
- R2, R3 and R4, which are identical or different, are such that one represents a halogen atom and the other two, which are identical or different, represent a hydrogen atom, a halogen atom or a methyl or methoxy radical, trifluoromethyl or trifluoromethoxy; and
- R5 represents a hydrogen atom;
- said products of formula (I) being in all isomeric forms possible racemic, enantiomers and diastereoisomers, as well as the addition salts with the mineral and organic acids of said products of formula (D
- R3 and R4 which are identical or different, are such that one represents a fluorine atom and the other two, which are identical or different, represent a hydrogen atom, a fluorine atom or a methyl radical;
- R5 represents a hydrogen atom; said products of formula (I) being in all isomeric forms possible racemic, enantiomers and diastereoisomers, as well as the addition salts with the mineral and organic acids of said products of formula (D);
- the subject of the present invention is in particular the products of formula (I) as defined above or below in which R, R1, R2, R3, R4, R5, R6, W, D, ring (Y) and cycle (N) have the meanings indicated above or below and Z represents SO 2, said products of formula (I) being in all isomeric forms possible racemic, enantiomers and diastereoisomers, as well as the addition salts with mineral acids and organic compounds of said formula (I).
- the subject of the present invention is in particular the products of formula (I) as defined above or below in which R, R1, R2, R3, R4, R5, R6, W, D, ring (Y) and cycle (N) have the meanings indicated above or below and Z represents CO, said products of formula (I) being in all possible isomeric forms racemic, enantiomers and Ddiastereoisomers, as well as the addition salts with mineral acids and organic of said products of formula (I).
- the subject of the present invention is in particular the process for the preparation of the products of formula (I) as defined above, characterized in that a product of formula (II) is converted into:
- R 1 and R 6 have the meanings given above for R 1 and R 6, respectively, in which the possible reactive functional groups are optionally protected by protective groups,
- R1 ', R2', R3 ', R4', R5 'and R6' have the meanings given above,
- products of formula (IA) I, (IA) 2, (IB) I and (IB) 2 which may be products of formula (I) in which, respectively, z represents SO2 or CO, and that, to obtain or to obtain Other products of formula (I) may be subjected, if desired and if necessary, to one or more of the following reaction reactions, in any order: a) an oxidation reaction of alkylthio group to sulfoxide or corresponding sulfone, b) a conversion reaction of alkoxy function in hydroxyl function, or of hydroxyl function in alkoxy function, c) an oxidation reaction of alcohol function as an aldehyde or ketone function, d) an elimination reaction of the protective groups that can be carried by the protected reactive functions, e) a salification reaction with an inorganic or organic acid to obtain the corresponding salt, f) a doubling reaction of the racemic forms into split products, said products of formula (I) thus obtained being in all possible isomeric forms racemic,
- the subject of the present invention is also a process for the preparation of the products of formula (I) as defined above corresponding to formula (IA) as defined above in which Y represents the radical NR10 as defined above.
- RIO represents CH2-RZ and RZ represents an alkyl, alkenyl or alkynyl radical, all optionally substituted with a naphthyl radical or with one or more identical or different radicals chosen from halogen atoms and phenyl and heteroaryl radicals, all these radicals; naphthyl, phenyl and heteroaryl being themselves optionally substituted with one or more identical or different radicals chosen from halogen atoms and hydroxyl, alkoxy, alkyl, hydroxyalkyl, alkoxyalkyl, CF3, NH2, NHaIk or N (alk) 2 radicals; characterized in that the compound of formula (XIV) is subjected to:
- R2 ', R3', R4 'and R5' have the meanings indicated in any of the other claims respectively for R2, R3, R4 and R5 in which the optional reactive functions are optionally protected by protecting groups, and z represents SO2 or CO, to a deprotection reaction of the carbamate function to obtain a product of formula (XV):
- products of formula (IA) which can be products of formula (I) and that in order to obtain or other products of formula (I), one or more reactions of transformations a) to f) can be subjected, if desired and if necessary, in any order; as defined above, said products of formula (I) thus obtained being in all the possible isomeric forms racemic, enantiomers and diastereoisomers.
- the processes described above can be carried out as follows:
- the product of formula (II) is converted into a product of formula (III) as defined above, especially in water in the presence of sodium hydroxide and methyl iodide at ordinary temperature.
- the product of formula (V) as defined above is converted into a product of formula (VI) by the action of phosphorus oxychloride POCl3 between 90 and 110 ° C. for one to two hours.
- the product of formula (VII) thus obtained is subjected to the action of an amine of formula (VIII) I or (VIII) 2 as defined above in particular in dichloromethane or a mixture of dichloromethane / THF or dimethylformamide with ambient temperature, in the presence of an organic base such as triethylamine, diisopropylethylamine or N-methyl morpholine, to obtain a product of formula (IX) Al or (IX) A2 as defined above.
- an organic base such as triethylamine, diisopropylethylamine or N-methyl morpholine
- the product of formula (IX) Al or (IX) A2 is reacted with a phenylboronic acid (X) as defined above according to the coupling methods of SUZUKI with an aryl or heteroaryl halide in the presence of a palladium catalyst.
- a palladium catalyst such as Pd (OAc) 2 or Pd (dba) 3 or else Pd (dba) 2, with a phosphine tritertiobutylphosphine or DPPF (I, 1'-bis (diphenylphosphino) ferrocene) or tricyclohexylphosphine.
- the product of formula (III) as defined above is subjected to the action of the methyl ester of 4-amino benzoic acid in particular in an alcohol such as butanol at a temperature of 100 to 140 ° C., to give the product of formula (XI) as defined above.
- This product of formula (XII) is saponified in its corresponding acid of formula (XIII) by proceeding according to the usual methods known to those skilled in the art such as in particular by the action of sodium hydroxide or potassium hydroxide in water.
- the product of formula (XIII) thus obtained is reacted with an amine of formula (VIII) I or (VIII) 2 as defined above according to the coupling methods known to those skilled in the art, such as, for example, amidic coupling in the presence of coupling agent such as BOP, DCC or TBTU in a solvent such as, for example, dimethylformamide or dichloromethane to obtain respectively a product of formula (IB) I or (IB) 2 as defined herein below above.
- the deprotection reaction of the carbamate function of the compound of formula (XIV) to obtain a product of formula (XV) can be carried out using, for example, an acidic agent such as pure trifluoroacetic acid at a temperature close to 0.degree.
- the product of formula (XV) is subjected to reductive amination conditions in the presence of the aldehyde or ketone of formula (XVI) to obtain a product of formula (IA) as defined above, for example with sodium borocyanide or sodium triacetoxyborohydride in a solvent such as methanol, tetrahydrofuran (THF) or their mixture in a pH medium of between 4 and 7.
- a suitable solvent such as methylene chloride at about 0 ° C. or else using hydrochloric acid dissolved in ether or dioxane at a temperature of between 0 ° C. and room temperature .
- the product of formula (XV) is subjected to reductive amination conditions in the presence of the aldehyde or ketone of formula (XVI) to obtain a product of formula (IA) as defined above, for example with sodium borocyanide or sodium triacetoxyborohydride in a solvent such as methanol, tetrahydro
- the products of formulas (IA) I, (IA) 2, (IB) I and (IB) 2 as defined above can therefore constitute products of formula (I) as defined above or can be converted into products of formula (I) by the usual methods known to those skilled in the art and by example by being subjected to one or more of the reactions a) to f) indicated above.
- the various reactive functions which certain compounds of the above-defined reactions may carry may, if necessary, be protected: for example, they are hydroxyl, acyl or amino and monoalkylamino radicals which may be protected by the appropriate protective groups.
- the following non-exhaustive list of examples of protection of reactive functions may be mentioned: the hydroxyl groups may be protected, for example, by alkyl radicals such as tert-butyl, trimethylsilyl, tert-butyldimethylsilyl, methoxymethyl, tetrahydropyranyl, benzyl or acetyl;
- the amino groups may be substituted, for example, by the acetyl, trityl, benzyl, tert-butoxycarbonyl, benzyloxycarbonyl or phthalimido radicals or other radicals known in the peptide chemistry and may then be released under the usual conditions known to man of career.
- the reactions to which the products of formula (I ') as defined above may be subjected, if desired or necessary, may be carried out, for example, as indicated below.
- the saponification reactions can be carried out according to the usual methods known to those skilled in the art, such as, for example, in a solvent such as methanol or ethanol, dioxane or dimethoxyethane, in the presence of sodium hydroxide or potassium hydroxide.
- the reduction or oxidation reactions may be carried out according to the usual methods known to those skilled in the art, such as, for example, in a solvent such as ethyl ether or tetrahydrofuran, in the presence of sodium borohydride or lithium aluminum hydride. ; or for example in a solvent such as acetone or tetrahydrofuran in the presence of potassium permanganate or pyridinium chlorochromate.
- sulfoxide function can be favored by an equimolar mixture of the product containing an alkylthio group and the reagent such as in particular a peracid.
- sulphone function can be promoted by a mixture of the product containing an alkylthio group with an excess of the reagent such as in particular a peracid.
- the optional alkoxy functions, such as methoxy in particular, of the products described above may, if desired, be converted into hydroxyl function under the usual conditions known to those skilled in the art, for example by boron tribromide in a solvent such as For example, methylene chloride, with hydrobromide or pyridine hydrochloride or with hydrobromic or hydrochloric acid in water or trifluoroacetic acid under reflux.
- the phthalimido group may in particular be eliminated with hydrazine.
- a list of different protective groups that can be used, for example, in the BF 2 499 995 patent can be found.
- the products described above may, if desired, be the subject of salification reactions for example by a mineral or organic acid according to the usual methods known to those skilled in the art.
- the optional optically active forms of the products described above may be prepared by resolution of the racemates according to the usual methods known to those skilled in the art.
- the starting products of formulas (II), (IV), (VIII) I and (VIII) 2 may be known, may be obtained commercially or may be prepared according to the usual methods known to those skilled in the art, in particular from commercial products for example by subjecting them to one or more reactions known to those skilled in the art such as for example the reactions described above in a) to f).
- the products of formula (II) which are therefore pyrimidine derivatives, for example dichloropyrimidine or trichloropyrimidine, are commercial products, as are boronic acids such as: -3,4,5-trifluorophenylboronic acid - 2,3,4-Trifluorophenylboronic acid
- the amines of formula (VIII) I or (VIII) 2 can also be commercially available, for example methyl (1- (methyl-piperidin-4-yl) amine. Preparations of the amines of formula (VIII) I or (VIII) 2 non-commercial can be carried out according to methods known to those skilled in the art.
- aldehydes or ketones of formula (XVI) are given in the experimental part as non-limiting examples.
- the present invention also relates to the process according to Scheme 1 below, for the preparation of products of formula (I) corresponding to formula (IB) as defined above:
- the radical NR8-CH (RA) (RB) represents certain values of NR8R9 as defined above with R8 as defined above and R9 represents -CH (RA) (RB) ie, as defined for R 9, a linear or branched alkyl radical optionally substituted by one or more radicals chosen from halogen atoms and hydroxyl, alkoxy, NH 2, NHalkyl, N (alkyl) 2, alkylthio, phenyl and saturated or unsaturated heterocycle radicals, phenyl and heterocycle themselves optionally substituted as indicated above.
- RA may represent a hydrogen atom or CH3
- RB may represent (CH2) pG with G represents an optionally substituted heterocycle or phenyl radical as defined above and p represents an integer of 0 to 5.
- the present invention also relates to the process according to Scheme 2 below for the preparation of products of formula (I) as defined above in which z represents CO:
- R2 ', R3', R4 ', R5', D 'and W have the meanings given above.
- the steps of the synthesis method of Scheme 2 above can be carried out using the methyl ester of aniline in step 2 and the boronic acids substituted by R2 ', R3' or R4 'in step 6 and by proceeding according to the usual methods known to those skilled in the art or as described in the present invention.
- Another subject of the present invention is, as new industrial products, certain compounds of formulas (XIV), (XV), (IX) Al, (IX) A2, (XII) and (XIII).
- the products of formula (I) as defined above and their addition salts with acids have interesting pharmacological properties.
- the compounds of the present invention can therefore inhibit the activity of kinases, in particular IKK1 and IKK2 with an IC50 of less than 10 ⁇ M.
- the compounds of the present invention can thus inhibit the activation of NF- ⁇ B, and the production of cytokines with IC 50 of less than 10 ⁇ M.
- the compounds of the present invention can thus inhibit the proliferation of a large panel of tumor cells with IC50 values of less than 10 ⁇ M.
- the compounds of formula (I) may therefore have drug activity in particular as inhibitors of IKK1 and IKK2 and may be used in the prevention or treatment of diseases in which the inhibition of IKK1 or IKK2 is beneficial.
- diseases such as inflammatory diseases or diseases with an inflammatory component such as inflammatory arthritis including rheumatoid arthritis, spondyl osteoarthritis, Reiters syndrome, psoriatic arthritis, bone resorption diseases; multiple sclerosis, inflammatory bowel disease including Crohn's disease; asthma, chronic pulmonary obstruction, emphysema, rhinitis, acquired myasthenia gravis, Graves' disease, transplant rejection, psoriasis, dermatitis, allergic disorders, systemic diseases immune system, cachexia, severe acute respiratory syndrome, septic shock, heart failure, myocardial infarction, atherosclerosis, reperfusion injury, AIDS, cancers and disorders characterized by resistance to insulin such as diabetes, hyperglycemia, hyperinsulinemia, dyslipidemia, obesity, polycystic ovarian diseases, hypertension, cardiovascular disorders, Syndrome X, autoimmune diseases such as systemic lupus, lupus erythematous, glomerular arthritis, and others.
- the products of formula (I) according to the present invention as modulators of apoptosis may be useful in the treatment of various human diseases including aberrations in apoptosis such as cancers: such as in particular but not limited to follicular lymphomas, carcinomas with p53 mutations, hormone-dependent tumors of the breast, prostate and ovary, and precancerous lesions such as polyposis familial adenoma, viral infections (such as, but not limited to, but not limited to those caused by Herpes virus, poxvirus, Epstein - Barr virus, Sindbis virus and adenovirus), myelodysplastic syndromes, ischemic disorders associated with myocardial infarction, cerebral congestion, arrhythmia, atherosclerosis, liver disorders induced by toxins or alcohol, haematological disorders such as, but not limited to, chronic anemia and aplastic anemia, degenerative diseases of the musculoskeletal system such as, but not limited to, osteoporosis, cystic fibrosis, kidney
- the compounds according to the invention have an anticancer activity and an activity in the treatment of other proliferative diseases such as psoriasis, restenosis, atherosclerosis, AIDS for example, as well as in diseases caused by proliferation.
- these compounds are useful in the prevention and treatment of leukemias, both primary and metastatic solid tumors, carcinomas and cancers, in particular: breast cancer, lung cancer, cancer of the lungs, small intestine, colon and rectal cancer, cancer of the respiratory tract, 1 oropharynx and 1 hypopharynx, esophageal cancer, liver cancer, stomach cancer, bile duct cancer, cancer of the gall bladder, pancreatic cancer, urinary tract cancers including kidney, urothelium and bladder, cancers of the female genital tract including cancer of the uterus, cervix, ovaries, chlorocarcinoma and trophoblastoma; cancers of the male genital tract including prostate cancer, seminal vesicles, testes, germ cell tumors; cancers of the endocrine glands including thyroid, pituitary, adrenal gland cancer; skin cancers including hemangiomas, melanomas, sarcomas, including Kaposi's s
- the compound (s) of formula (I) may be administered in combination with one or more anti-cancer active principle (s), in particular antitumor compounds such as alkylating agents such as alkylsulfonates ( busulfan), dacarbazine, procarbazine, nitrogen mustards (chlormethine, melphalan, chlorambucil), cyclophosphamide, ifosfamide; nitrosoureas such as carmustine, lomustine, semustine, streptozocin; antineoplastic alkaloids such as vincristine, vinblastine; taxanes such as paclitaxel or taxotere; antineoplastic antibiotics such as actinomycin; intercalators, antineoplastic antimetabolites, folate antagonists, methotrexate; inhibitors of purine synthesis; purine analogues such as mercaptopurine, 6-thioguanine; inhibitors of pyrimidine synthesis, aromatase
- the compounds of formula (I) may also be administered in combination with one or more other active ingredients useful in one of the pathologies indicated above, for example an anti-emetic, anti-pain, anti-inflammatory agent, anticachexie.
- the subject of the present invention is thus, as medicaments, the products of formula (I) as defined above as well as the addition salts with pharmaceutically acceptable inorganic and organic acids of said products of formula (I).
- the subject of the present invention is, in particular, as medicaments, the products of formula (I) as defined above, the names of which follow:
- the subject of the present invention is also the pharmaceutical compositions containing, as active principle, at least one of the products of formula (I) as defined above or a pharmaceutically acceptable salt of this product or a prodrug of this product and a pharmaceutically acceptable carrier.
- the present invention particularly relates to the use of the products of formula (I) as defined above or pharmaceutically acceptable salts thereof for the preparation of a medicament for the treatment or prevention of a disease by inhibition of IKK protein kinase activity.
- the present invention thus relates to the use as defined above in which the protein kinase is in a mammal.
- the subject of the present invention is therefore the use of a product of formula (I) as defined above for the preparation of a medicinal product intended for the treatment or the prevention of a disease chosen from the diseases indicated above.
- the subject of the present invention is in particular the use of a product of formula (I) as defined above for the preparation of a medicament for the treatment or prevention of a disease chosen from the following group: inflammatory diseases, diabetes and cancers.
- the present invention particularly relates to the use of a product of formula (I) as defined above for the preparation of a medicament for the treatment or prevention of inflammatory diseases.
- the present invention particularly relates to the use of a product of formula (I) as defined above for the preparation of a medicament for the treatment or prevention of diabetes.
- the present invention particularly relates to the use of a product of formula (I) as defined above for the preparation of a medicament for the treatment of cancers.
- the present invention particularly relates to the use of a product of formula (I) as defined above for the treatment of solid or liquid tumors.
- the present invention particularly relates to the use of a product of formula (I) as defined above for the treatment of cancers resistant to cytotoxic agents.
- the subject of the present invention is in particular the use of a product of formula (I) as defined above for the preparation of drugs for the chemotherapy of cancers.
- the subject of the present invention is in particular the use of a product of formula (I) as defined above for the preparation of medicaments intended for cancer chemotherapy alone or in combination or in combination form as defined herein. -above.
- the present invention particularly relates to the use of a product of formula (I) as defined above as inhibitors of IKK.
- the present invention particularly relates to the products of formula (I) as defined above which constitute Examples 1 to 69 of the present invention.
- the following examples illustrate the invention without, however, limiting it.
- a solution containing 15 g of 2-anilino-pyrimidin-4-ol in 75 ml of POCl3 is heated at 110 ° C. for 2 h. After evaporation of POCL3, the crude reaction product is tranvased in an ice-cold solution of Na2CO3. 16.3 g of the expected product are obtained by filtration of the precipitate.
- Step 4 2 - [(2-Chloropyrimidin-4-yl) amino] -benzenesulfonyl chloride hydrochloride:
- Step 1 1-Oxa-6-aza-spiro [2.5] octane-6-carboxylic acid tert-butyl ester
- Step 2 4-Hydroxy-4-pyrrolidin-1-ylmethyl-piperidine-1-carboxylic acid tert-butyl ester
- Step 1 ⁇ 1- [4- (4-Chloro-pyrimidin-2-ylamino) -benzenesulfonyl] -piperidin-4-yl ⁇ -methyl-carbamic acid tert-butyl ester:
- Step 3 [4- (4-Fluoro-phenyl) -pyrimidin-2-yl] - [4- (4-methylamino-piperidine-1-sulfonyl) -phenyl] -amine:
- the product obtained (1.77 g) at this stage 2 is put in MeOH and then a large volume of 2N solution of HCl in dioxane is added. After one night of reaction, the crude reaction product is concentrated to dryness and then taken up in a mixture AcOEt / NaOH (IN). The aqueous phase is extracted by AcOEt. After drying over MgSO 4 and concentration in vacuo, 1.3 g of expected product are obtained.
- Step 1 4- ⁇ [4- (4-Chloro-pyrimidin-2-ylamino) -benzenesulfonyl] -methyl-amino ⁇ -piperidine-1-carboxylic acid tert-butyl ester
- Step 1 of Procedure 2 from 7 g of the compound of Procedure la and 4,932 g of 4-methylamino-piperidine-1-carboxylic acid tert-butyl ester ester, 8.8 g of expected product are obtained. .
- Step 2 4- ( ⁇ 4- [4- (4-Fluoro-phenyl) -pyrimidin-2-ylamino] -benzenesulfonyl ⁇ -methyl-amino) -piperidine-1-carboxylic acid tert-butyl ester
- Step 3 4- [4- (4-Fluoro-phenyl) -pyrimidin-2-ylamino] -N-methyl-N-piperidin-4-yl-benzenesulfonamide
- Step 1 (2 - ⁇ (1-Benzyl-piperidin-4-yl) - [4- (4-chloropyrimidin-2-ylamino) -benzenesulfonyl] -amino ⁇ -ethyl) -carbamic acid tert-butyl ester
- Step 2 [2- (1-Benzyl-piperidin-4-yl) - ⁇ 4- [4- (4-fluoro-phenyl) -pyrimidin-2-ylamino] -benzenesulfonyl ⁇ -amino) -ethyl] -carbamic acid tert-butyl ester
- Step 3 N- (2-Amino-ethyl) -N- (1-benzyl-piperidin-4-yl) -4- (4- (4-fluoro-phenyl) -pyrimidin-2-ylamino] -benzenesulfonamide
- Step 1 [2- ( ⁇ 4- [4- (4-Fluoro-phenyl) -pyrimidin-2-ylamino] -benzenesulfonyl ⁇ -piperidin-4-yl-amino) -ethyl] -carbamic acid tert-butyl ester proceeds by hydrogenolysis reaction from 250 mg of the compound obtained in Step 1 of Example 5 which is reacted Presence of 50 mg of ammonium formate and 20 mg of Pd / C with 3 mL MeOH in a microwave reactor (250 W, 80 ° C. for 5 minutes). 90 mg of expected product is thus obtained.
- Step 2 N- (2-Aminoethyl) -4- [4- (4-fluoro-phenyl) -pyrimidin-2-ylamino] -N-piperidin-4-yl-benzenesulfonamide
- Example 25 In the same manner as in Example 2 [reaction of the sulfonamide of Example 1 with commercial aldehydes (or ketones)], the following compounds (Table 25 below) which are Examples 7 to 31 of this invention) are obtained by adapting the procedure according to the procedure described below: To 0.10 mmol of the product of the procedure 2 in 2.0 mL of THF, a solution of 0.12 mmol of aldehyde in 1.0 mL of THF and 0.3 mL of AcOH is added. Finally, 128 mg of CNBH3-bearing polymer are added and the mixture is stirred under an argon atmosphere overnight at RT. The reaction mixture is filtered, the filtrate is washed with 5 ml of THF and concentrated in vacuo. The crude reaction product is dissolved in 2 ml of DMF and purified by preparative preparative HPLC to give the expected product described as trifluoroacetic acid salt.
- Examples 32 to 47 are synthesized following the procedure described in Step 2 of Example 1 from the compound of Procedure 3a (below) and corresponding boronic acids.
- Examples 48 to 69 are synthesized following the procedure described in Step 2 of Example 1 from the compound of Procedure 3b or Procedure 3c (below) and corresponding boronic acids.
- Procedure 3b (4- ⁇ 4- [Amino-R- (4-fluoro-phenyl) -methyl] -piperidine-1-sulfonyl ⁇ -phenyl) - (4-chloro-pyrimidin-2-yl) -amine
- Example 2 is taken by way of example in the pharmaceutical preparation which constitutes Example 32 above, this pharmaceutical preparation being able to be carried out differently as indicated above and if desired with other products exemplified herein. request.
- IKK2 using a kinase test on flash-plate support.
- the compounds to be tested are dissolved at 10 mM in DMSO and then diluted in kinase buffer (50 mM Tris, pH 7.4 containing 0.1 mM EGTA, 0.1 mM sodium orthovanadate and 0.1% p-mercaptoethanol). Serial 3-to-3 dilutions are made from this solution. 10 .mu.l of each dilution are added to the wells of a 96-well plate in duplicate. 10 ⁇ l of kinase buffer is added to the control wells which will serve as 0% inhibition and 10 ⁇ l of 0.5 mM EDTA is added to the control wells (100% inhibition).
- the compounds of the invention tested in this test show an IC50 of less than 10 ⁇ M, which shows that they can be used for their therapeutic activity.
- the compounds according to the invention have been the subject of pharmacological tests for determining their anticancer activity.
- the compounds of formula (I) according to the present invention have been tested in vitro on a panel of tumor lines of human origin originating from: breast cancer: MDA-MB231 (American type culture collection, Rockville, Maryland, USA, ATCC -HTB26), MDA-A1 or MDA-ADR (MDR-resistant multi-drug line, and described by E.Collomb et al., In Cytometry, 12 (1): 15-
- HCT116 ATCC-CCL247
- HCT15 ATCC-CCL225
- lung cancer H460 (described by Carmichael in Cancer Research 47 (4): 936-942, 1987 and issued by
- CLT1 described by Kuriyama et al., in Blood, 74: 1989, 1381-1387, by Soda et al in British Journal of Haematology, 59: 1985, 671-679 and by Drexler, in Leukemia Research, 18: 1994, 919-927 and issued by DSMZ, Mascheroder Weg Ib, 38124 Braunschweig, Germany.
- Proliferation and cell viability were determined in a test using 3- (4,5-dimethylthiazol-2-yl) -5- (3-carboxymethoxyphenyl) -2- (4-sulfophenyl) -2H-tetrazolium (MTS) according to Fujishita T.
- the mitochondrial capacity of the living cells is measured to transform the MTS into a colored compound after 72 hours of incubation of a compound of formula (I) according to the invention.
- concentrations of compound according to the invention, which lead to 50% loss of proliferation and cell viability (IC50) are less than 10 microM, depending on the tumor line and the test compound.
- the compounds of formula (I) lead to a loss of proliferation and viability of the tumor cells with an IC 50 of less than 10 ⁇ M.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0700065A FR2911139A1 (fr) | 2007-01-05 | 2007-01-05 | Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
PCT/FR2008/000003 WO2008099074A1 (fr) | 2007-01-05 | 2008-01-02 | Derives de phenyl- (4-phenyl-pyrimidin-2-yl) - amines comme inhibiteurs de ikk, leur preparation et leur compositions pharmaceutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2111395A1 true EP2111395A1 (fr) | 2009-10-28 |
Family
ID=38290127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08761728A Withdrawn EP2111395A1 (fr) | 2007-01-05 | 2008-01-02 | Derives de phenyl- (4-phenyl-pyrimidin-2-yl) - amines comme inhibiteurs de ikk, leur preparation et leur compositions pharmaceutiques |
Country Status (11)
Country | Link |
---|---|
US (1) | US20100069417A1 (es) |
EP (1) | EP2111395A1 (es) |
JP (1) | JP2010514822A (es) |
CN (1) | CN101600697A (es) |
AR (1) | AR064731A1 (es) |
CA (1) | CA2673532A1 (es) |
CL (1) | CL2008000022A1 (es) |
FR (1) | FR2911139A1 (es) |
TW (1) | TW200848048A (es) |
UY (1) | UY30858A1 (es) |
WO (1) | WO2008099074A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007079078A1 (en) | 2005-12-29 | 2007-07-12 | Bayer Schering Pharma Aktiengesellschaft | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
AU2013201306B2 (en) * | 2007-03-12 | 2015-11-12 | Glaxosmithkline Llc | Phenyl Amino Pyrimidine Compounds and Uses Thereof |
AU2016200866B2 (en) * | 2007-03-12 | 2017-06-22 | Glaxosmithkline Llc | Phenyl amino pyrimidine compounds and uses thereof |
KR101737753B1 (ko) * | 2007-03-12 | 2017-05-18 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
CA2777762A1 (en) * | 2009-10-12 | 2011-04-21 | Myrexis, Inc. | Amino - pyrimidine compounds as inhibitors of tbk1 and/or ikk epsilon |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
GB201012105D0 (en) * | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
EP2696683A4 (en) * | 2011-04-12 | 2014-08-13 | Alzheimer S Inst Of America Inc | COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF IKK-MEDIATED KINASE EPSILON AND TANK BINDING KINASE-1 HEMMER |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
RU2686101C2 (ru) | 2013-03-12 | 2019-04-24 | Селтакссис, Инк. | Способы ингибирования лейкотриен- а4-гидролазы |
CA2906086A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
WO2014152518A2 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
BR112015022226A2 (pt) | 2013-03-14 | 2017-07-18 | Celtaxsys Inc | inibidores de leucotrieno a4 hidrolase |
TWI729644B (zh) | 2014-06-12 | 2021-06-01 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
BR112016029662B1 (pt) | 2014-06-19 | 2023-10-24 | Takeda Pharmaceutical Company Limited | COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
CN106866684B (zh) * | 2015-12-10 | 2020-06-09 | 吴耀东 | 用于治疗肿瘤的大环衍生物 |
JP7266592B2 (ja) * | 2017-10-17 | 2023-04-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリミジンTBK/IKKεインヒビター化合物およびそれらの使用 |
BR112020007549A2 (pt) | 2017-10-17 | 2020-09-24 | Merck Patent Gmbh | compostos inibidores de pirimidina tbk/ikképsilon e uso dos mesmos |
US10898484B2 (en) | 2018-05-31 | 2021-01-26 | Celltaxis, Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
TW202128675A (zh) | 2019-12-06 | 2021-08-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑之經取代四氫呋喃 |
US11827627B2 (en) | 2021-06-04 | 2023-11-28 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
EP1598343A1 (de) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
KR20070084067A (ko) * | 2004-10-13 | 2007-08-24 | 와이어쓰 | N-벤젠설포닐 치환 아닐리노-피리미딘 동족체 |
FR2911137B1 (fr) * | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de 2,4-dianilinopyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
-
2007
- 2007-01-05 FR FR0700065A patent/FR2911139A1/fr not_active Withdrawn
-
2008
- 2008-01-02 CA CA002673532A patent/CA2673532A1/fr not_active Abandoned
- 2008-01-02 CN CNA2008800035978A patent/CN101600697A/zh active Pending
- 2008-01-02 JP JP2009544427A patent/JP2010514822A/ja not_active Withdrawn
- 2008-01-02 WO PCT/FR2008/000003 patent/WO2008099074A1/fr active Application Filing
- 2008-01-02 EP EP08761728A patent/EP2111395A1/fr not_active Withdrawn
- 2008-01-03 AR ARP080100013A patent/AR064731A1/es unknown
- 2008-01-03 CL CL200800022A patent/CL2008000022A1/es unknown
- 2008-01-04 UY UY30858A patent/UY30858A1/es not_active Application Discontinuation
- 2008-01-04 TW TW097100461A patent/TW200848048A/zh unknown
-
2009
- 2009-07-01 US US12/496,105 patent/US20100069417A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2008099074A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2010514822A (ja) | 2010-05-06 |
FR2911139A1 (fr) | 2008-07-11 |
CL2008000022A1 (es) | 2008-05-16 |
CA2673532A1 (fr) | 2008-08-21 |
TW200848048A (en) | 2008-12-16 |
UY30858A1 (es) | 2008-09-02 |
WO2008099074A1 (fr) | 2008-08-21 |
CN101600697A (zh) | 2009-12-09 |
AR064731A1 (es) | 2009-04-22 |
US20100069417A1 (en) | 2010-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2111395A1 (fr) | Derives de phenyl- (4-phenyl-pyrimidin-2-yl) - amines comme inhibiteurs de ikk, leur preparation et leur compositions pharmaceutiques | |
EP2108016A1 (fr) | Derives de 2 -anilino 4 -heteroaryle pyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk | |
WO2007006926A2 (fr) | Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk | |
EP2104673A2 (fr) | Nouveaux derives de 2, 4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk | |
FR2911138A1 (fr) | Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk | |
RU2422449C2 (ru) | Фармацевтические соединения | |
FR2919869A1 (fr) | Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk | |
EP1812439B2 (en) | Kinase inhibitors | |
EA007298B1 (ru) | Гетероариламины в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3) | |
CA2718488A1 (fr) | Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation | |
EP3194403A1 (en) | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists | |
CA2812686A1 (en) | Benzazole derivatives as histamine h4 receptor ligands | |
AU2015291477A1 (en) | Novel 2,5-substituted pyrimidines as PDE inhibitors | |
FR2888239A1 (fr) | Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk | |
CA2784153A1 (fr) | Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75 | |
FR2893941A1 (fr) | Nouveaux derives de 2,4-dianilinopyridines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk | |
JP4384505B2 (ja) | ファルネシルトランスフェラーゼを阻害する炭素連結イミダゾールもしくはトリアゾール置換三環状キナゾリン誘導体 | |
FR3061177A1 (fr) | Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090805 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
17Q | First examination report despatched |
Effective date: 20091218 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100629 |